VEKLURY 100 MG — DIN 02502143
REMDESIVIR : 100 MG · GILEAD SCIENCES CANADA INC · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is VEKLURY?
VEKLURY 100 MG contains REMDESIVIR : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02502143, held by GILEAD SCIENCES CANADA INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 16-Oct-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is VEKLURY used for?
VEKLURY (remdesivir) is indicated for the treatment of coronavirus disease 2019 (COVID-19) in: • Hospitalized adults and pediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen. • Non-hospitalized adults and pediatric patients (weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death (see 14 Clinical Trials).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Remdesivir cost around the world?
Remdesivir is listed on 3 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Italy publishes a ex-factory (classe H); Saudi Arabia publishes a public. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Bahrain | retail (max) | 1 | 1 | BHD███.██ |
| Italy | ex-factory (classe H) | 1 | 1 | EUR███.██ |
| Saudi Arabia | public | 1 | 1 | SAR███.██ |
3 pack listings across 3 brand entries and 3 price bases, refreshed 02 Sep 2026. Ranges span every Remdesivir pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Remdesivir in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Remdesivir — 2 DINs, of which 1 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| GILEAD SCIENCES CANADA INC | 2 | 1 | VEKLURY | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 100 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | Packaged in a single Type 1 clear glass vial, an elastomeric closure, and an aluminum overseal with a flip-off cap. |
| Storage | Unopened vials: Store below 30°C. Reconstituted and diluted solution for infusion: Store diluted remdesivir solution for infusion up to 4 hours below 25°C or up to 24 hours in a refrigerator (2°C to 8°C). Once reconstituted, the drug product should be diluted immediately. Once diluted, the drug product should be used immediately. If necessary, bags of diluted solution can be stored for up to 4 hours below 25°C, or for up to 24 hours in a refrigerator. Do not allow more than 24 hours between dilution and administration. Do not reuse or save unused remdesivir powder or diluted solution for infusion for future use. This product contains no preservative. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Remdesivir |
|---|---|
| ATC code | J05AB16 |
| AHFS class | 08:18.32 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02502143 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2502143 |
| Brand name | VEKLURY |
| Generic / active ingredient | REMDESIVIR : 100 MG |
| Market authorization holder | GILEAD SCIENCES CANADA INC |
| Health Canada schedule | Prescription |
| ATC code | J05AB16 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J05AB |
| Current status | MARKETED |
| Status date | 16-Oct-2020 |
| Original market date | 2020-10-16 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
VEKLURY is administered as an intravenous infusion. It must not be given as an intramuscular (IM) injection. The powder for solution for infusion is for administration by intravenous infusion after reconstitution and further dilution. Recommended Dose in Adults and Pediatric Patients (weighing at least 40 kg): Day 1 (single loading dose): 200 mg Day 2 and onwards (once daily): 100 mg Recommended Dose in Pediatric Patients (at least 4 weeks old, weighing at least 3 kg but less than 40 kg): Day 1 (single loading dose): 5 mg/kg Day 2 and onwards (once daily): 2.5 mg/kg Treatment Duration: Hospitalized patients with pneumonia and requiring supplemental oxygen: Adults and Pediatric patients (weighing at least 40 kg): Daily for at least 5 days and not more than 10 days. Pediatric patients (at least 4 weeks old, weighing at least 3 kg but less than 40 kg): Daily for up to a total of 10 days. Non-hospitalized patients who are at increased risk for progressing to severe COVID-19: Adults and Pediatric patients (weighing at least 40 kg): Daily for 3 days, starting as soon as possible after diagnosis of COVID-19 and within 7 days of the onset of symptoms. Reconstitution: VEKLURY must be reconstituted with 19 mL sterile water for injections and diluted in sodium chloride 9 mg/mL (0.9%) solution for injection before being administered via intravenous infusion over 30 to 120 minutes. Aseptic conditions are required. The vial should be shaken for 30 seconds, allowed to settle for 2-3 minutes, and repeated if not completely dissolved. Dilute immediately after reconstitution. Infusion Rates: Vary based on infusion bag volume and infusion time, ranging from 0.21 mL/min to 8.33 mL/min.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
VEKLURY is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see 6 Dosage Forms, Strengths, Composition and Packaging.
Warnings and precautions
Hypersensitivity reactions including infusion-related and anaphylactic reactions have been observed during and following administration of VEKLURY. Signs and symptoms may include hypotension, hypertension, tachycardia, bradycardia, hypoxia, fever, dyspnea, wheezing, angioedema, rash, nausea, vomiting, diaphoresis, and shivering. Monitor patients for hypersensitivity reactions during and following administration of VEKLURY. For infusion-related reactions, slower infusion rates, with a maximum infusion time of up to 120 minutes, can be considered to potentially prevent these signs and symptoms. If signs and symptoms of a clinically significant hypersensitivity reaction occur, immediately discontinue administration of VEKLURY and initiate appropriate treatment.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
1 of 2 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| VEKLURY | 100 MG / 20 ML | SOLUTION | GILEAD SCIENCES CANADA INC | CANCELLED PRE MARKET | 02502135 |
2 · Same class — other molecules in ATC J05AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Valaciclovir | AG-VALACYCLOVIR · APO-VALACYCLOVIR · AURO-VALACYCLOVIR · BIO-VALACYCLOVIR · +17 more | 36 | 22 | Yes |
| Acyclovir | ACYCLOVIR · ACYCLOVIR SODIUM FOR INJECTION · ACYCLOVIR SODIUM INJECTION · ACYCLOVIR-200 · +17 more | 48 | 15 | Yes |
| Famciclovir | ACT FAMCICLOVIR · APO-FAMCICLOVIR · AURO-FAMCICLOVIR · AVA-FAMCICLOVIR · +7 more | 36 | 6 | Yes |
| Valganciclovir | APO-VALGANCICLOVIR · AURO-VALGANCICLOVIR · MINT-VALGANCICLOVIR · MYLAN-VALGANCICLOVIR · +3 more | 9 | 6 | Yes |
| Ganciclovir | CYTOVENE · CYTOVENE - CAP 250MG · CYTOVENE INJ 500MG/VIAL · CYTOVENE, 500 MG · +2 more | 9 | 4 | Yes |
| Remdesivir | VEKLURY | 2 | 1 | Yes |
| Cidofovir | MAR-CIDOFOVIR | 1 | 1 | Yes |
| Brincidofovir | TEMBEXA | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J05A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J05AR | Antivirals For Treatment Of Hiv Infections, Combinations · Atanazavir And Cobicistat · Darunavir And Cobicistat · Dolutegravir And Rilpivirine · Emtricitabine And Tenofovir Alafenamide · +16 more | 56 | 39 |
| J05AF | Abacavir · Adefovir Dipivoxil · Didanosine · Emtricitabine · Entecavir · +7 more | 71 | 39 |
| J05AH | Neuraminidase Inhibitors · Oseltamivir · Zanamivir | 33 | 16 |
| J05AX | Baloxavir Marboxil · Bulevirtide · Enfuvirtide · Fostemsavir · Inosine Pranobex · +5 more | 19 | 14 |
| J05AE | Amprenavir · Atazanavir · Darunavir · Fosamprenavir · Indinavir · +5 more | 75 | 14 |
| J05AG | Delavirdine · Doravirine · Efavirenz · Etravirine · Nevirapine · +1 more | 22 | 10 |
| J05AJ | Cabotegravir · Dolutegravir · Elvitegravir · Raltegravir | 12 | 6 |
| J05AP | Asunaprevir · Boceprevir · Daclatasvir · Dasabuvir, Ombitasvir, Paritaprevir And Ritonavir · Elbasvir And Grazoprevir · +8 more | 22 | 6 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is VEKLURY called?
Also recorded in Canada as: remdesivir 100 MG Injection [Veklury] (US), 20 ML remdesivir 5 MG/ML Injection [Veklury] (US), remdesivir 100 MG Injection (US), 20 ML remdesivir 5 MG/ML Injection (US), REMDESIVIR (US), Covifor (IN), Cipremi (IN), Remdac (IN), Desrem (IN), Remdesivir (GLOBAL), Remidia (BD).
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.